Search research articles
Contact Us
Filters
Showing results (71-80 of 156) with videos related to
Page
of 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
July 3, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study
Vittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
Michele Cavo, Francesco Di Raimondo, Elena Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Blood
|
March 12, 2010
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability
Barbara Sarina, Luca Castagna, Lucia Farina, et al.
European Journal of Haematology
|
November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Francesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Lancet (London, England)
|
December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Blood
|
June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Francesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Bone Marrow Transplantation
|
April 15, 2020
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
Luciano J Costa, Simona Iacobelli, Marcelo C Pasquini, et al.
Annals of Hematology
|
May 11, 2013
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation
Carolina Terragna, Matteo Renzulli, Daniel Remondini, et al.
Bone Marrow Transplantation
|
November 27, 2019
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
Giulia Tolomelli, Katia Mancuso, Paola Tacchetti, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 156) with videos related to
Sort By:
Page
of 16
Clinical Lymphoma, Myeloma & Leukemia
|
July 3, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study
Vittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
Michele Cavo, Francesco Di Raimondo, Elena Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Blood
|
March 12, 2010
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability
Barbara Sarina, Luca Castagna, Lucia Farina, et al.
European Journal of Haematology
|
November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Francesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Lancet (London, England)
|
December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Blood
|
June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Francesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Bone Marrow Transplantation
|
April 15, 2020
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
Luciano J Costa, Simona Iacobelli, Marcelo C Pasquini, et al.
Annals of Hematology
|
May 11, 2013
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation
Carolina Terragna, Matteo Renzulli, Daniel Remondini, et al.
Bone Marrow Transplantation
|
November 27, 2019
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
Giulia Tolomelli, Katia Mancuso, Paola Tacchetti, et al.
Page
of 16